Phase 1, randomized, double-blind, placebo-controlled single ascending dose clinical study assessing ENX104 in healthy volunteers
Latest Information Update: 20 Sep 2024
At a glance
- Drugs ENX 104 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; First in man
- 20 Sep 2024 New trial record
- 18 Sep 2024 According to Engrail Therapeutics media release, the company announces initiation of this trial